Effect of different doses of Lacticaseibacillus paracasei K56 on body fat and metabolic parameters in adult individuals with obesity: a pilot study

Table 5 Quantitative analysis of K56 in feces at the baseline and day 60 by qPCR

Group	Baseline		60 days		Increased fecal K56 level^b
Group	Detected positive^a	Average quantity in positive samples [log^{concentration}/ul original DNA]	Detected positive	Average quantity in positive samples [log^{concentration}/ul original DNA]	Increased fecal K56 level^b
Placebo	4/14	4.331 ± 0.270	3/14	4.887 ± 0.672	0/14
VL_K56	6/15	4.411 ± 1.481	11/15	3.526 ± 1.166	9/15
L_K56	4/14	4.098 ± 1.683	14/14	2.990 ± 0.991	12/14
H_K56	4/14	4.797 ± 1.003	13/14	1.930 ± 1.333	12/14
VH_K56	7/15	4.836 ± 1.049	15/15	1.685 ± 1.356	15/15

^aFeces samples were analyzed from all participants who had returned both baseline and after intervention samples
^bParticipants were considered have increased fecal K56 levels when the K56 concentration was at least one log higher at the end-of-study compared to baseline, while when the concentration was undetectable or remained within one log compared to baseline they were considered didn’t have increases

ISSN: 1743-7075